Next Article in Journal
Transcriptomic Differences Underlying the Activin-A Induced Large Osteoclast Formation in Both Healthy Control and Fibrodysplasia Ossificans Progressiva Osteoclasts
Previous Article in Journal
Mixed-Linkage Glucan Is the Main Carbohydrate Source and Starch Is an Alternative Source during Brachypodium Grain Germination
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 7
10.3390/ijms24076832
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Effect of Cytomegalovirus Reactivation on Inflammatory Status and Mortality of Older COVID-19 Patients

by
Robertina Giacconi
1,*,
Maurizio Cardelli
1,
Francesco Piacenza
1,
Elisa Pierpaoli
1,
Elisabetta Farnocchia
1,
MirKo Di Rosa
2,
Anna Rita Bonfigli
3,
Tiziana Casoli
4,
Francesca Marchegiani
5,
Fiorella Marcheselli
5,
Rina Recchioni
5,
Pierpaolo Stripoli
5,
Roberta Galeazzi
6,
Antonio Cherubini
7,
Massimiliano Fedecostante
7,
Riccardo Sarzani
8,9,
Chiara Di Pentima
8,9,
Piero Giordano
8,9,
Roberto Antonicelli
10,
Mauro Provinciali
1 and
Fabrizia Lattanzio
3add Show full author list remove Hide full author list
1
Advanced Technology Center for Aging Research, IRCCS INRCA, Via Birarelli 8, 60121 Ancona, Italy
2
Unit of Geriatric Pharmacoepidemiology and Biostatistics, IRCCS INRCA, 60124 Ancona, Italy
3
Scientific Direction, IRCCS INRCA, 60124 Ancona, Italy
4
Center for Neurobiology of Aging, IRCCS INRCA, 60121 Ancona, Italy
5
Center of Clinical Pathology and Innovative Therapy, IRCCS INRCA, 60121 Ancona, Italy
6
Clinical Laboratory and Molecular Diagnostic, Italian National Research Center on Aging, IRCCS INRCA, 60127 Ancona, Italy
7
Geriatria, Accettazione Geriatrica e Centro di Ricerca per L’invecchiamento, IRCCS INRCA, 60127 Ancona, Italy
8
Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, 60126 Ancona, Italy
9
Internal Medicine and Geriatrics, Italian National Research Centre on Aging, Hospital “U. Sestilli”, IRCCS INRCA, 60127 Ancona, Italy
10
Cardiology Unit, IRCCS INRCA, 60129 Ancona, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(7), 6832; https://doi.org/10.3390/ijms24076832
Submission received: 18 January 2023 / Revised: 16 March 2023 / Accepted: 30 March 2023 / Published: 6 April 2023
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Browse Figures
Review Reports Versions Notes

Abstract

:
Herpesviridae reactivation such as cytomegalovirus (CMV) has been described in severe COVID-19 (COronaVIrusDisease-2019). This study aimed to understand if CMV reactivation in older COVID-19 patients is associated with increased inflammation and in-hospital mortality. In an observational single-center cohort study, 156 geriatric COVID-19 patients were screened for CMV reactivation by RT-PCR. Participants underwent a comprehensive clinical investigation that included medical history, functional evaluation, laboratory tests and cytokine assays (TNF-α, IFN-α, IL-6, IL-10) at hospital admission. In 19 (12.2%) of 156 COVID-19 patients, CMV reactivation was detected. Multivariate Cox regression models showed that in-hospital mortality significantly increased among CMV positive patients younger than 87 years (HR: 9.94, 95% CI: 1.66–59.50). Other factors associated with in-hospital mortality were C-reactive protein (HR: 1.17, 95% CI: 1.05–1.30), neutrophil count (HR: 1.20, 95% CI: 1.01–1.42) and clinical frailty scale (HR:1.54, 95% CI: 1.04–2.28). In patients older than 87 years, neutrophil count (HR: 1.13, 95% CI: 1.05–1.21) and age (HR: 1.15, 95% CI: 1.01–1.31) were independently associated with in-hospital mortality. CMV reactivation was also correlated with increased IFN-α and TNF-α serum levels, but not with IL-6 and IL-10 serum changes. In conclusion, CMV reactivation was an independent risk factor for in-hospital mortality in COVID-19 patients younger than 87 years old, but not in nonagenarians.

1. Introduction

Herpesviridae reactivation is frequent in critically ill patients, including those affected by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) [1,2,3,4]. After primary infection, herpesvirus can produce a latent infection, and once the balance between the host immunity and the latent virus is broken, especially in older immunosuppressed COVID-19 (coronavirus disease 2019 caused by SARS-CoV-2) patients, herpesvirus proliferation can cause serious illness, involving multiple organs (liver, lung and brain) [5,6,7].
Among herpesviruses, cytomegalovirus (CMV) has been associated with digestive symptoms, gastrointestinal complications and bleedings in COVID-19 patients [8,9]. Moreover, CMV reactivation has been related to various adverse clinical outcomes, such as prolonged mechanical ventilation (MV), extracorporeal membrane oxygenation (ECMO) duration, increased length of hospitalization, and mortality [10,11,12]. In older subjects, CMV infection influences the maturation and long-term composition of the immune repertoire [13]. Importantly, CMV causes clonal T cell proliferation with an expansion in the number of virus-specific effector and memory cells, and a substantial reduction in naïve T cell diversity [14,15]. This phenomenon may lead to a reduced immune response to novel viral infections such as SARS-CoV-2. Severe COVID-19 is correlated with a dysregulated innate immune response, including a limited and delayed type I interferon (IFN) response and hyperinflammation [16]. Evidence shows that higher CMV viremia is associated with increased IL-6 production [17] and could fuel the cytokine storm in COVID-19 patients [18].
Although many factors have been associated with a poor prognosis in patients with COVID-19 infection, including genetic and laboratory parameters [19,20,21], investigating the impact of CMV reactivation, especially in the oldest old patients could be extremely useful for early identification of subjects at risk of developing severe complications and death.

2. Results

The clinical characteristics of COVID-19 patients included in this study are summarized in Table 1. Among the 156 patients, 19 were CMV DNAemia positive (12.2%), and the mean age and gender distribution were similar between CMV positive and CMV negative patients. The incidence of CMV reactivation did not change in relation to the main comorbidities. No difference in CRP, neutrophil and lymphocyte counts, neutrophil/lymphocyte ratio, fibrinogen, D-dimer concentrations, clinical frailty scale, presence at admission of respiratory insufficiency, fever and cough was found between groups. CMV IgM antibodies were also tested. Overall, 21% (4/19) of patients with CMV DNAemia were CMV IgM positive, while among the patients without CMV DNAemia, 4.4% (4/137) resulted as CMV IgM positive (Table S1, supplementary material). Moreover, CMV IgM positive patients showed similar IFN-α and TNF-α levels to CMV IgM negative patients, but lower than patients with CMV DNAemia (Table S2, supplementary material).
Since previous evidence has shown that CMV T-cell changes were associated with mortality in older subjects under 85 years of age, but not in older ones [22], to investigate the possible association of CMV reactivation with in-hospital death, we stratified the patient cohort according to the median age. Table 2 reports the frequency distribution of CMV positive patients in relation to in-hospital death after age-stratification. In the group with age < 87 years (mean age 79.9 ± 5.7), the in-hospital mortality was higher in patients with CMV reactivation than without reactivation (50% vs. 13.2%; p < 0.01).
Cox regression analysis indicated that the risk of a poor prognosis in patients younger than 87 years with CMV viremia was 9.9 times higher than that in patients without CMV reactivation (p < 0.05) (Table 3). Other predictors of in-hospital death were CRP, neutrophil count and frailty status (CSF). In patients older than 87 years (mean age 90.7 ± 3.2), age and neutrophil count were the only factors significantly associated with increased mortality. In-hospital death was not associated with the number of patients’ comorbidities in either age groups.
Accordingly, survival analysis indicated that patients with CMV reactivation and younger than 87 years had a lower survival than CMV negative patients, while no difference was observed in nonagenarian patients (over 87 years of age) (Figure 1).
Cytomegalovirus (CMV); chronic obstructive pulmonary disease (COPD); ischemic heart disease (IHD); atrial fibrillation (AF); chronic kidney disease (CKD), C-reactive protein (CRP), neutrophil/lymphocyte ratio (NLR); clinical frailty scale (CSF); and interquartile range (IQR).
Kaplan–Meier plots compared in-hospital mortality between CMV positive (green line) and CMV negative patients (blue line). Panel A: Patients younger than 87 years with CMV reactivation had a lower survival than CMV negative ones. Panel B: CMV reactivation was not a predictor of in-hospital death in nonagenarian patients.
IFN-α and TNF-α serum levels were higher in CMV positive patients than CMV negative ones. No difference was observed for IL-6 and IL-10 serum concentrations. Data were analyzed in the whole patient cohort.
ANCOVA analysis correcting for age and sex. * p < 0.05; ** p < 0.01.

3. Discussion

COVID-19 is characterized by a mild to severe respiratory illness, which is influenced by age and comorbidities [23,24,25]. Older patients, presenting a chronic pro-inflammatory status and immunosenescence, have an increased risk to develop COVID-19 severe outcomes including mortality [26]. T cells have a crucial role in controlling viral infections. CMV seroprevalence increases with age, reaching 85–90% by 75–80 years [27,28]. In the elderly, CMV causes clonal T cell proliferation, and reduction in naïve T cell diversity, which in turn may lead to reduced immune responsiveness to novel viral infections such as SARS-CoV-2, making older people particularly susceptible to severe COVID-19 [29].
On the other hand, it has also been observed that the reactivation of endogenous latent viruses such as HSV and CMV is quite common in critically ill patients and immunosuppressed patients [30]. CMV reactivation has been associated with an increased risk of hospitalization due to SARS-CoV-2 infection [31]. In this study, we found that 12% of elderly COVID-19 patients presented CMV reactivation, in agreement with previous studies [4,32]. Moreover, CMV positive patients younger than 87 years had a higher risk of in-hospital mortality than those without CMV reactivation. Consistent with other investigations, we also found that CRP, neutrophil count and frailty status were significantly associated with in-hospital death [33,34,35], whereas in patients older than 87 years, who were more susceptible to mortality from SARS-CoV-2 infection with respect to the younger group (45% vs. 17%), CMV DNAemia was not associated with death. In accordance with previous evidence, in the oldest group the main factors related to in-hospital mortality were age and an increased neutrophil count [34,35,36]. The lack of association between CMV reactivation and in-hospital mortality in the oldest patients could seem unexpected, because of evidence from longitudinal studies, where nonagenarians show CMV T-cell changes (oligoclonal, memory T cells, a reduction in the naïve T cells), in turn associated with frailty and increased mortality [14,37]. However, our results could be partly explained by the findings of Johnstone et al. [22], who demonstrated that CMV-reactive CD4+ T-cells were predictive of mortality within 1 year in subjects aged 65 to 84, but not in the oldest ones (aged 85–104 years). However, due to the limited number of CMV positive nonagenarians, our finding should be confirmed in a larger population.
It is still unclear whether CMV reactivation occurs in the context of severe SARS-CoV-2 infection or whether ongoing CMV infection influences the pathogenesis of COVID-19. CMV IgM detection revealed that 21% (4/19) of patients with CMV DNAemia were CMV IgM positive, while among patients without CMV DNAemia, 4.4% (4/137) resulted as CMV IgM positive. However, it is likely that in very old patients IgM positivity does not indicate primary CMV infection but a condition of immunosuppression likely due to high-dose corticosteroid treatment [38].
However, different conditions associated with SARS-CoV-2 infection such as lymphocyte depletion, glucocorticoid therapy and the advanced age are all factors favoring CMV reactivation. In our cohort, glucocorticoid treatment was not associated with the risk of CMV-infection (8.3% in CMV positive vs. 12.9% in CMV negative patients, p = 0.531 Pearson Chi-square test). Moreover, even if lymphocyte count was not significantly different between CMV negative and CMV positive patients, a marked reduction of the total number of NK and CD8+ T cells in patients with SARS-CoV-2 infection has been demonstrated, a condition that may lead to immunosuppression favoring CMV reactivation [39].
It has been found that CMV replication predominates in the lung, a major reservoir for CMV, and local reactivation may cause lung injury and hyperinflammation, resulting in complications in critically ill patients [38,40]. Similarly to SARS-CoV-2 virus, CMV induces the production of cytokines and chemokines that can exacerbate inflammation, contributing to a cytokine storm in COVID-19 patients [41,42,43]. In this regard, we found increased TNF-α serum levels in CMV positive patients, although no difference in IL-6 and IL-10 serum concentrations was present between CMV positive and CMV negative patients.
Interestingly, CMV positive patients also had increased IFN-α serum levels that might be a response to CMV reactivation to counteract virus replication [44].
Type I interferons (IFNs) have emerged as crucial contributors to the immune response against a SARS-CoV-2 infection [45,46]. Previous findings suggested that an impaired IFN-I response could be an important contributor to the disease severity in SARS-CoV-2 infection [45,46,47]. However, recent evidence shows that serum IFN-I levels in the early phase of SARS-CoV-2 infection are increased in patients who develop hypoxemic respiratory failure [48]. In our study, the levels of cytokines in serum were measured within one week after symptom onset, therefore the increased early IFN-α response in CMV positive patients could contribute to disease severity.
This study has some limitations, in particular the retrospective design, the small sample size of our cohort with a reduced number of CMV positive patients and the evaluation of a single outcome, i.e., in-hospital mortality. Furthermore, we did not evaluate the effect of treatments performed during admission, which might influence patients’ evolution.
Therefore, the study results need to be confirmed in a larger patient cohort.
In summary, older COVID-19 patients may present CMV reactivation, which could aggravate the disease course, influencing IFN-α and TNF-α production and increasing the risk of in-hospital death in elderly octogenarian patients. However, to better understand how CMV may influence the severity of illness and whether CMV specific antiviral treatment may improve the prognosis in older patients with CMV reactivation, further investigations are needed.

4. Materials and Methods

4.1. Patients Recruitment

This study includes 156 patients with COVID-19, who were recruited between 1 October 2020 and 24 June 2021 in the framework of the Report-Age COVID-19 project, an observational study conducted at the Italian National Center on Aging (IRCCS INRCA). The mean age of patients was 85.4 ± 7.1. Nasopharyngeal and throat swab samples were obtained at admission from all patients who were tested using the real-time polymerase chain reaction (RT-PCR) assay to identify SARS-CoV-2 infection. All patients were unvaccinated against SARS-CoV-2. No patients underwent invasive mechanical ventilation, but were supported with non-invasive oxygen therapy. The study was approved by the Ethics Committee of IRCCS INRCA (number CE-INRCA-20008) and registered under the ClinicalTrials.gov database (reference number NCT04348396). All patients signed informed consent. All study protocols were performed in alignment with local and international guidelines and regulations, and the research has been conducted in accordance with the Declaration of Helsinki.

4.2. Data Collection

The clinical records and laboratory data of each patient were obtained from the electronic medical system and were anonymized before release. Clinical data included symptoms and signs of infection such as fever, cough, dyspnea, diarrhea, nausea, and vomitting. Frailty was graded according to the Rockwood Clinical Frailty Scale (CFS) [49]. The CFS is an ordinal scale that ranks frailty from 1 to 9 (from being very fit to severely frail and terminally ill), with higher scores indicating progressively higher degrees of frailty.
Comorbidities were assessed including hypertension, diabetes mellitus, chronic obstructive pulmonary disease, ischemic heart disease, atrial fibrillation, dementia and chronic kidney disease. Laboratory parameters at admission, including those for complete blood count, serum concentrations of C-reactive protein (CRP), and D-dimer, were tested in the IRCCS INRCA laboratory using standardized and certified procedures.

4.3. CMV Detection

Total viral DNA was extracted from 140 µL of plasma using QIAamp Viral RNA Mini Kit (QIAGEN, Milan, Italy) and following the manufacturer’s protocol.
Real-time quantitative PCR was performed using the following primers for CMV detection:
Forward 5′-CAGTCCCGAGACMGTGAGAC-3′;
Reverse 5′-TGAACATCCCCAGCATCAACG-3′.
A total volume of 15 μL was used, with 0.3 µM of each primer, 7.5 μL of iTaq Universal SYBR Green Supermix (Biorad, Milan, Italy) and 3 μL of DNA for CMV assay. All reactions were performed on Rotor-Gene Q (QIAGEN, Milan, Italy), with the following conditions: 3 min at 95 °C, 45 cycles of 15 s at 95 °C, and 30 s at 60 °C. Positive control DNA (AcroMetrix CMV High Controls) and negative template controls were included on each assay.
All samples were run on duplicate arrays, and discordant results run a third time. The plasma sample was considered positive for the CMV DNAemia when detected with a cycle threshold (CT) < 38.

4.4. Detection of IgM Antibodies to CMV

The CMV IgM were measured in serum samples with LIAISON® CMV IgM II chemiluminescent immunoassay (Diasorin, Vercelli, Italy) following the manufacturer’s protocol. IgM were equivocal for values ≥ 18 U/mL and <22 U/mL or positive for values ≥ 22 U/mL.

4.5. Cytokine Determination

Serum IL-6, IL-10, TNF-α, and IFN-α were measured by using the high-sensitivity ProQuantum qPCR immunoassays (Thermo Fisher, Waltham, MA, USA) measured on the Aria Mix real-time PCR system (Agilent, Santa Clara, CA, USA) following the manufacturer protocol. Each sample was assayed in duplicate.

4.6. Statistical Analyses

Log transformation of the variables was carried out if they were not normally distributed as assessed by the Kolmogorov–Smirnov test. Patient characteristics were reported as mean ± standard error of the mean (SEM) or median values and interquartile range (IQR) for continuous variables, or absolute frequency and percentages for categorical variables. Differences between groups were analyzed by t test or Mann–Whitney test for continuous variables and Pearson’s χ2 test for categorical variables. ANOVA (after correction for age and sex) was used to evaluate differences in inflammatory and coagulation markers, between patients with or without CMV reactivation. The relationship between CMV reactivation and mortality was investigated by Kaplan–Meier and Cox regression analyses.
The main factors included in the Cox regression model were age, sex, disease count, CRP, CMV, neutrophil count and clinical frailty scale.
Disease count represented all diseases included in our dataset, in particular: hypertension, diabetes, chronic obstructive pulmonary disease, asthma, ischemic heart disease, dementia, atrial fibrillation and chronic kidney disease.
Statistical significance was set to 2-sided p < 0.05.
Statistical analyses were performed using SPSS (Version 27.0.1.0, IBM, Amenk, NY, USA).

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24076832/s1.

Author Contributions

Conceptualization, R.G. (Robertina Giacconiand); methodology, R.G. (Robertina Giacconiand), F.P., M.C., E.F., P.S., R.G. (Roberta Galeazzi), F.M. (Fiorella Marcheselli), F.M. (Francesca Marchegianiand), T.C., R.R. and E.P.; software, M.D.R.; BioBank, R.G. (Roberta Galeazzi) and A.R.B.; recruitment of subjects and collection of clinical information, A.C., M.F., R.S., P.G., C.D.P. and R.A.; validation, R.G. (Robertina Giacconiand) and E.F.; formal analysis, F.P., M.C., R.G. (Roberta Galeazzi), F.M. (Fiorella Marcheselli), F.M. (Francesca Marchegianiand), T.C., R.R., E.P., A.R.B., M.P. and F.L.; investigation, R.G. (Robertina Giacconiand); resources, F.L.; data curation, M.D.R., R.G. (Robertina Giacconiand), F.P. and M.C.; writing—original draft preparation, R.G. (Robertina Giacconiand) writing—Review and Editing, R.G. (Robertina Giacconiand), F.P., M.C., F.M. (Fiorella Marcheselli), F.M. (Francesca Marchegianiand), T.C., R.R., E.P., A.R.B. and R.G. (Roberta Galeazzi), A.R.B., R.S., M.F., A.C., R.A., M.P. and F.L.; supervision, M.P. and F.L.; funding acquisition, M.P. and F.L. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Italian Health Ministry (Ricerca Corrente to IRCCS INRCA) and MARCHE Region.

Institutional Review Board Statement

This study was conducted in accordance with the ethical norms and standards of the Declaration of Helsinki for clinical research. The study was approved by the Ethics Committee of IRCCS INRCA (number CE-INRCA-20008) and registered under the ClinicalTrials.gov database (reference number NCT04348396).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The datasets analyzed in this study are available from the corresponding author upon reasonable request.

Acknowledgments

The authors thank BioGer, the IRCCS INRCA Institutional Biobank for providing the samples and Belinda Giorgetti, Beatrice Bartozzi, and Denise Quinzi for their invaluable work in the detection of SARS-Cov-2 infection by performing real-time reverse transcriptase-polymerase chain reaction assays in nasal/oro-pharyngeal swab samples.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Le Balc’h, P.; Pinceaux, K.; Pronier, C.; Seguin, P.; Tadié, J.M.; Reizine, F. Herpes Simplex Virus and Cytomegalovirus Reactivations among Severe COVID-19 Patients. Crit. Care 2020, 24, 530. [Google Scholar] [CrossRef]
  2. Xu, R.; Zhou, Y.; Cai, L.; Wang, L.; Han, J.; Yang, X.; Chen, J.; Chen, J.; Ma, C.; Shen, L. Co-Reactivation of the Human Herpesvirus Alpha Subfamily (Herpes Simplex Virus-1 and Varicella Zoster Virus) in a Critically Ill Patient with COVID-19. Br. J. Dermatol. 2020, 183, 1145–1147. [Google Scholar] [CrossRef] [PubMed]
  3. Simonnet, A.; Engelmann, I.; Moreau, A.S.; Garcia, B.; Six, S.; El Kalioubie, A.; Robriquet, L.; Hober, D.; Jourdain, M. High Incidence of Epstein–Barr Virus, Cytomegalovirus, and Human-Herpes Virus-6 Reactivations in Critically Ill Patients with COVID-19. Infect. Dis. Now 2021, 51, 296–299. [Google Scholar] [CrossRef] [PubMed]
  4. Saade, A.; Moratelli, G.; Azoulay, E.; Darmon, M. Herpesvirus Reactivation during Severe COVID-19 and High Rate of Immune Defect. Infect. Dis. Now 2021, 51, 676–679. [Google Scholar] [CrossRef] [PubMed]
  5. Busani, S.; Bedini, A.; Biagioni, E.; Serio, L.; Tonelli, R.; Meschiari, M.; Franceschini, E.; Guaraldi, G.; Cossarizza, A.; Clini, E.; et al. Two Fatal Cases of Acute Liver Failure Due to HSV-1 Infection in COVID-19 Patients Following Immunomodulatory Therapies. Clin. Infect. Dis. 2021, 73, E252–E255. [Google Scholar] [CrossRef]
  6. Ramirez-Colombres, M.; Maenza, C.E.; Rocchetti, N.S.; Gattino, S.P.; Diodati, S.; Luchitta, C.A.; Ré, M.D.; Settecase, C.J.; Bagilet, D.H. COVID-19 and Herpesvirus Encephalitis. Rev. Neurol. 2022, 74, 280–283. [Google Scholar] [CrossRef] [PubMed]
  7. Aldehaim, A.Y.; Alfaifi, A.M.; Hussain, S.N.; Alrajhi, A.M. Cytomegalovirus Pneumonitis amid COVID-19 Chaos: The Hidden Enemy—A Case Report. J. Med. Case Rep. 2022, 16, 58. [Google Scholar] [CrossRef]
  8. Amaral, P.; Ferreira, B.; Roll, S.; Neves, P.; Pivetta, L.; Mohrbacher, S.; Dias, E.; Sato, V.; Oliveira, É.; Pereira, L.; et al. COVID-19 and Cytomegalovirus Co-Infection: A Challenging Case of a Critically Ill Patient with Gastrointestinal Symptoms. Eur. J. Case Rep. Intern. Med. 2020, 7, 001911. [Google Scholar] [CrossRef]
  9. Geisen, W.R.; Berger, J.; Schwartz, C.; Reddy, A.; Rai, B.; Wadih, G.; Peck, J. Cytomegalovirus Enterocolitis Secondary to Experimental COVID-19 Therapy. IDCases 2020, 22, e00962. [Google Scholar] [CrossRef]
  10. Ong, D.S.Y.; Spitoni, C.; Klein Klouwenberg, P.M.C.; Verduyn Lunel, F.M.; Frencken, J.F.; Schultz, M.J.; van der Poll, T.; Kesecioglu, J.; Bonten, M.J.M.; Cremer, O.L. Cytomegalovirus Reactivation and Mortality in Patients with Acute Respiratory Distress Syndrome. Intensive Care Med. 2016, 42, 333–341. [Google Scholar] [CrossRef] [Green Version]
  11. Lachance, P.; Chen, J.; Featherstone, R.; Sligl, W.I. Association between Cytomegalovirus Reactivation and Clinical Outcomes in Immunocompetent Critically Ill Patients: A Systematic Review and Meta-Analysis. In Open Forum Infectious Diseases; Oxford University Press: New York, NY, USA, 2017; Volume 4. [Google Scholar] [CrossRef] [Green Version]
  12. Hraiech, S.; Bonnardel, E.; Guervilly, C.; Fabre, C.; Loundou, A.; Forel, J.M.; Adda, M.; Parzy, G.; Cavaille, G.; Coiffard, B.; et al. Herpes Simplex Virus and Cytomegalovirus Reactivation among Severe ARDS Patients under Veno-Venous ECMO. Ann. Intensive Care 2019, 9, 142. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Kallemeijn, M.J.; Boots, A.M.H.; Van Der Klift, M.Y.; Brouwer, E.; Abdulahad, W.H.; Verhaar, J.A.N.; Van Dongen, J.J.M.; Langerak, A.W. Ageing and Latent CMV Infection Impact on Maturation, Differentiation and Exhaustion Profiles of T-Cell Receptor Gammadelta T-Cells. Sci. Rep. 2017, 7, 5509. [Google Scholar] [CrossRef] [Green Version]
  14. Hadrup, S.R.; Strindhall, J.; Køllgaard, T.; Seremet, T.; Johansson, B.; Pawelec, G.; thor Straten, P.; Wikby, A. Longitudinal Studies of Clonally Expanded CD8 T Cells Reveal a Repertoire Shrinkage Predicting Mortality and an Increased Number of Dysfunctional Cytomegalovirus-Specific T Cells in the Very Elderly. J. Immunol. 2006, 176, 2645–2653. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Almanzar, G.; Schwaiger, S.; Jenewein, B.; Keller, M.; Herndler-Brandstetter, D.; Würzner, R.; Schönitzer, D.; Grubeck-Loebenstein, B. Long-Term Cytomegalovirus Infection Leads to Significant Changes in the Composition of the CD8 + T-Cell Repertoire, Which May Be the Basis for an Imbalance in the Cytokine Production Profile in Elderly Persons. J. Virol. 2005, 79, 3675–3683. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Lee, J.S.; Shin, E.C. The Type I Interferon Response in COVID-19: Implications for Treatment. Nat. Rev. Immunol. 2020, 20, 585–586. [Google Scholar] [CrossRef]
  17. Li, H.; Weng, P.; Najarro, K.; Xue, Q.-L.; Semba, R.D.; Margolick, J.B.; Leng, S.X. Chronic CMV Infection in Older Women: Longitudinal Comparisons of CMV DNA in Peripheral Monocytes, Anti-CMV IgG Titers, Serum IL-6 Levels, and CMV Pp65 (NLV)-Specific CD8+ T-Cell Frequencies with Twelve Year Follow-Up. Exp. Gerontol. 2014, 54, 84–89. [Google Scholar] [CrossRef] [Green Version]
  18. Xu, B.; Fan, C.Y.; Wang, A.L.; Zou, Y.L.; Yu, Y.H.; He, C.; Xia, W.G.; Zhang, J.X.; Miao, Q. Suppressed T Cell-Mediated Immunity in Patients with COVID-19: A Clinical Retrospective Study in Wuhan, China. J. Infect. 2020, 81, e51–e60. [Google Scholar] [CrossRef]
  19. Abdelzaher, H.; Saleh, B.M.; Ismail, H.A.; Hafiz, M.; Gabal, M.A.; Mahmoud, M.; Hashish, S.; Gawad, R.M.A.; Gharieb, R.Y.; Abdelnaser, A. COVID-19 Genetic and Environmental Risk Factors: A Look at the Evidence. Front. Pharmocol. 2020, 11, 579415. [Google Scholar] [CrossRef]
  20. Jiang, Y.; Abudurexiti, S.; An, M.M.; Cao, D.; Wei, J.; Gong, P. Risk Factors Associated with 28-Day All-Cause Mortality in Older Severe COVID-19 Patients in Wuhan, China: A Retrospective Observational Study. Sci. Rep. 2020, 10, 22369. [Google Scholar] [CrossRef]
  21. Knopp, P.; Miles, A.; Webb, T.E.; Mcloughlin, B.C.; Mannan, I.; Raja, N.; Wan, B.; Davis, D. Presenting Features of COVID-19 in Older People: Relationships with Frailty, Inflammation and Mortality. Eur. Geriatr. Med. 2020, 11, 1089–1094. [Google Scholar] [CrossRef]
  22. Johnstone, J.; Parsons, R.; Botelho, F.; Millar, J.; McNeil, S.; Fulop, T.; McElhaney, J.E.; Andrew, M.K.; Walter, S.D.; Devereaux, P.J.; et al. T-Cell Phenotypes Predictive of Frailty and Mortality in Elderly Nursing Home Residents. J. Am. Geriatr. Soc. 2017, 65, 153–159. [Google Scholar] [CrossRef] [PubMed]
  23. Aktar, S.; Talukder, A.; Ahamad, M.M.; Kamal, A.H.M.; Khan, J.R.; Protikuzzaman, M.; Hossain, N.; Azad, A.K.M.; Quinn, J.M.W.; Summers, M.A.; et al. Machine Learning Approaches to Identify Patient Comorbidities and Symptoms That Increased Risk of Mortality in COVID-19. Diagnostics 2021, 11, 1383. [Google Scholar] [CrossRef]
  24. Lim, J.P.; Low, K.Y.H.; Lin, N.J.J.; Lim, C.Z.Q.; Ong, S.W.X.; Tan, W.Y.T.; Tay, W.C.; Tan, H.N.; Young, B.E.; Lye, D.C.B.; et al. Predictors for Development of Critical Illness amongst Older Adults with COVID-19: Beyond Age to Age-Associated Factors. Arch. Gerontol. Geriatr. 2021, 94, 104331. [Google Scholar] [CrossRef] [PubMed]
  25. Strazhesko, I.; Tkacheva, O.; Kashtanova, D.; Ivanov, M.; Kljashtorny, V.; Esakova, A.; Karnaushkina, M.; Guillemette, C.; Hewett, A.; Legault, V.; et al. Physiological Health Indexes Predict Deterioration and Mortality in Patients With Covid-19: A Comparative Study. Aging 2022, 14, 1611–1626. [Google Scholar] [CrossRef] [PubMed]
  26. Sabbatinelli, J.; Matacchione, G.; Giuliani, A.; Ramini, D.; Rippo, M.R.; Procopio, A.D.; Bonafè, M.; Olivieri, F. Circulating Biomarkers of Inflammaging as Potential Predictors of COVID-19 Severe Outcomes. Mech. Ageing Dev. 2022, 204, 111667. [Google Scholar] [CrossRef]
  27. Noronha, B.P.; de Mambrini, J.V.M.; Torres, K.C.L.; Martins-Filho, O.A.; Teixeira-Carvalho, A.; Lima-Costa, M.F.; Peixoto, S.V. Cytomegalovirus and Herpes Simplex Type 1 Infections and Immunological Profile of Community-Dwelling Older Adults. Exp. Gerontol. 2021, 149, 111337. [Google Scholar] [CrossRef]
  28. Souquette, A.; Frere, J.; Smithey, M.; Sauce, D.; Thomas, P.G. A Constant Companion: Immune Recognition and Response to Cytomegalovirus with Aging and Implications for Immune Fitness. GeroScience 2017, 39, 293–303. [Google Scholar] [CrossRef] [Green Version]
  29. Kadambari, S.; Klenerman, P.; Pollard, A.J. Why the Elderly Appear to Be More Severely Affected by COVID-19: The Potential Role of Immunosenescence and CMV. Rev. Med. Virol. 2020, 30, e2144. [Google Scholar] [CrossRef]
  30. Cantan, B.; Luyt, C.E.; Martin-Loeches, I. Influenza Infections and Emergent Viral Infections in Intensive Care Unit. Semin. Respir. Crit. Care Med. 2019, 40, 488–497. [Google Scholar] [CrossRef] [Green Version]
  31. Alanio, C.; Verma, A.; Mathew, D.; Gouma, S.; Liang, G.; Dunn, T.; Oldridge, D.A.; Weaver, J.; Kuri-Cervantes, L.; Pampena, M.B.; et al. Cytomegalovirus Latent Infection Is Associated with an Increased Risk of COVID-19-Related Hospitalization. J. Infect. Dis. 2022, 226, 463–473. [Google Scholar] [CrossRef]
  32. Qu, J.; He, F.; Li, H.; Lv, X. Emergent Virus Reactivation in SARS-CoV-2-Negative Community Acquired Pneumonia Patients During the COVID-19 Pandemic. Front. Microbiol. 2022, 13, 758073. [Google Scholar] [CrossRef] [PubMed]
  33. Kurien, S.S.; David, R.S.; Chellappan, A.K.; Varma, R.P.; Pillai, P.R.; Yadev, I. Clinical Profile and Determinants of Mortality in Patients With COVID-19: A Retrospective Analytical Cross-Sectional Study in a Tertiary Care Center in South India. Cureus 2022, 14, e23103. [Google Scholar] [CrossRef] [PubMed]
  34. Olivieri, F.; Sabbatinelli, J.; Bonfigli, A.R.; Sarzani, R.; Giordano, P.; Cherubini, A.; Antonicelli, R.; Rosati, Y.; Del Prete, S.; Di Rosa, M.; et al. Routine Laboratory Parameters, Including Complete Blood Count, Predict COVID-19 in-Hospital Mortality in Geriatric Patients. Mech. Ageing Dev. 2022, 204, 111674. [Google Scholar] [CrossRef] [PubMed]
  35. Falandry, C.; Bitker, L.; Abraham, P.; Subtil, F.; Collange, V.; Balança, B.; Haïne, M.; Guichon, C.; Leroy, C.; Simon, M.; et al. Senior-COVID-Rea Cohort Study: A Geriatric Prediction Model of 30-Day Mortality in Patients Aged over 60 Years in ICU for Severe COVID-19. Aging Dis. 2022, 13, 614–623. [Google Scholar] [CrossRef]
  36. Roig, S.O.; Soler-Blanco, N.; Jiménez, I.T.; den Otero, E.V.E.; Moreno-Ariño, M.; Gómez-Valent, M. Clinical and Pharmacological Data in Covid-19 Hospitalized Nonagenarian Patients. Rev. Esp. Quimioter. 2021, 34, 145–150. [Google Scholar] [CrossRef]
  37. Spyridopoulos, I.; Martin-Ruiz, C.; Hilkens, C.; Yadegarfar, M.E.; Isaacs, J.; Jagger, C.; Kirkwood, T.; von Zglinicki, T. CMV Seropositivity and T-Cell Senescence Predict Increased Cardiovascular Mortality in Octogenarians: Results from the Newcastle 85+ Study. Aging Cell 2016, 15, 389–392. [Google Scholar] [CrossRef] [Green Version]
  38. Naendrup, J.H.; Garcia Borrega, J.; Eichenauer, D.A.; Shimabukuro-Vornhagen, A.; Kochanek, M.; Böll, B. Reactivation of EBV and CMV in Severe COVID-19-Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients. J. Intensive Care Med. 2022, 37, 1152–1158. [Google Scholar] [CrossRef]
  39. Zheng, M.; Gao, Y.; Wang, G.; Song, G.; Liu, S.; Sun, D.; Xu, Y.; Tian, Z. Functional Exhaustion of Antiviral Lymphocytes in COVID-19 Patients. Cell. Mol. Immunol. 2020, 17, 533–535. [Google Scholar] [CrossRef] [Green Version]
  40. Farber, D.L.; Yudanin, N.A.; Restifo, N.P. Human Memory T Cells: Generation, Compartmentalization and Homeostasis. Nat. Rev. Immunol. 2014, 14, 24–35. [Google Scholar] [CrossRef] [Green Version]
  41. Zheng, Q.; Tao, R.; Gao, H.; Xu, J.; Shang, S.; Zhao, N. HCMV-Encoded UL128 Enhances TNF-α and IL-6 Expression and Promotes PBMC Proliferation through the MAPK/ERK Pathway in vitro. Viral Immunol. 2012, 25, 98–105. [Google Scholar] [CrossRef] [Green Version]
  42. Murayama, T.; Kikuchi, M.; Miita, T.; Yamada, R.; Matsubara, K.; Sadanari, H.; Mukaida, N. Human Cytomegalovirus Replication Supported by Virus-Induced Activation of CCL2-CCR2 Interactions. Biochem. Biophys. Res. Commun. 2014, 453, 321–325. [Google Scholar] [CrossRef] [PubMed]
  43. Peluso, M.J.; Deveau, T.M.; Munter, S.E.; Ryder, D.; Buck, A.; Beck-Engeser, G.; Chan, F.; Lu, S.; Goldberg, S.A.; Hoh, R.; et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Investig. 2023, 133, e163669. [Google Scholar] [CrossRef]
  44. Holzki, J.K.; Dağ, F.; Dekhtiarenko, I.; Rand, U.; Casalegno-Garduño, R.; Trittel, S.; May, T.; Riese, P.; Čičin-Šain, L. Type I Interferon Released by Myeloid Dendritic Cells Reversibly Impairs Cytomegalovirus Replication by Inhibiting Immediate Early Gene Expression. J. Virol. 2015, 89, 9886–9895. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Hadjadj, J.; Yatim, N.; Barnabei, L.; Corneau, A.; Boussier, J.; Smith, N.; Péré, H.; Charbit, B.; Bondet, V.; Chenevier-Gobeaux, C.; et al. Impaired Type I Interferon Activity and Inflammatory Responses in Severe COVID-19 Patients. Science 2020, 369, 718–724. [Google Scholar] [CrossRef]
  46. Acharya, D.; Liu, G.Q.; Gack, M.U. Dysregulation of Type I Interferon Responses in COVID-19. Nat. Rev. Immunol. 2020, 20, 397–398. [Google Scholar] [CrossRef] [PubMed]
  47. Bastard, P.; Rosen, L.B.; Zhang, Q.; Michailidis, E.; Hoffmann, H.H.; Zhang, Y.; Dorgham, K.; Philippot, Q.; Rosain, J.; Béziat, V.; et al. Autoantibodies against Type I IFNs in Patients with Life-Threatening COVID-19. Science 2020, 370, eabd4585. [Google Scholar] [CrossRef] [PubMed]
  48. Nagaoka, K.; Kawasuji, H.; Murai, Y.; Kaneda, M.; Ueno, A.; Miyajima, Y.; Fukui, Y.; Morinaga, Y.; Yamamoto, Y. Circulating Type I Interferon Levels in the Early Phase of COVID-19 Are Associated With the Development of Respiratory Failure. Front. Immunol. 2022, 13, 844304. [Google Scholar] [CrossRef]
  49. Rockwood, K.; Song, X.; MacKnight, C.; Bergman, H.; Hogan, D.B.; McDowell, I.; Mitnitski, A. A Global Clinical Measure of Fitness and Frailty in Elderly People. CMAJ 2005, 173, 489–495. [Google Scholar] [CrossRef] [Green Version]
Ijms 24 06832 g001 550
Figure 1. Kaplan–Meier survival estimates according to CMV reactivation in old COVID-19 patients stratified by age. Kaplan-Meier plots comparing in-hospital mortality between CMV positive (green line) and CMV negative patients (blue line). Panel A: Patients younger than 87 years with CMV reactivation had a lower survival than CMV negative ones. Panel B: CMV reactivation was not a predictor of in-hospital death in nonagenarian pa-tients.CMV reactivation was also associated with increased IFN-α and TNF-α serum levels, while no difference was observed for IL-6 and IL-10 serum concentrations in the whole patient cohort (Figure 2).
Figure 1. Kaplan–Meier survival estimates according to CMV reactivation in old COVID-19 patients stratified by age. Kaplan-Meier plots comparing in-hospital mortality between CMV positive (green line) and CMV negative patients (blue line). Panel A: Patients younger than 87 years with CMV reactivation had a lower survival than CMV negative ones. Panel B: CMV reactivation was not a predictor of in-hospital death in nonagenarian pa-tients.CMV reactivation was also associated with increased IFN-α and TNF-α serum levels, while no difference was observed for IL-6 and IL-10 serum concentrations in the whole patient cohort (Figure 2).
Ijms 24 06832 g001
Ijms 24 06832 g002 550
Figure 2. Serum cytokine concentrations in COVID-19 patients according to CMV reactivation. IFN-α and TNF-α serum levels were higher in CMV positive patients than CMV negative ones. No difference was observed for IL-6 and IL-10 serum concentrations. Data were analyzed in the in the whole patient cohort. ANCOVA analysis correcting for age and sex * p < 0.05; ** p < 0.01.
Figure 2. Serum cytokine concentrations in COVID-19 patients according to CMV reactivation. IFN-α and TNF-α serum levels were higher in CMV positive patients than CMV negative ones. No difference was observed for IL-6 and IL-10 serum concentrations. Data were analyzed in the in the whole patient cohort. ANCOVA analysis correcting for age and sex * p < 0.05; ** p < 0.01.
Ijms 24 06832 g002
Table
Table 1. Baseline clinical patient characteristics.
Table 1. Baseline clinical patient characteristics.
Non-CMV Reactivation
n = 137		CMV Reactivation
n = 19		p Value
Age, mean ± SEM85.22 ± 0.6187.26 ± 1.640.245
Male sex, n(%)54 (39.7%)5 (25.0%)0.199
Hypertension, n (%)97 (71.0%)12 (63.1%)0.269
Diabetes, n (%)33 (24.1%)4 (21.0%)0.496
COPD, n (%)20 (14.6%)2 (10.5%)0.770
IHD, n (%)17 (12.4%)4 (21.0%)0.300
AF, n (%)36 (26.2%)9 (47.0%)0.057
Alzheimer, n (%)14 (10.2%)2 (10.5%)0.967
CKD, n (%)35 (25.5%)4 (21.0%)0.671
Respiratory insufficiency, n (%)100 (73.0%)14 (73.7%)0.949
Fever, n (%)66 (48.2%)11 (57.8%)0.427
Cough, n (%)33 (24.0%)5 (25.0%)0.832
CRP (mg/L), mean ± SEM5.41 ± 0.515.24 ± 1.330.821
Lymphocytes (103/µL), mean ± SEM1.28 ± 0.071.07 ± 0.180.248
Neutrophils (103/µL), mean ± SEM7.16 ± 0.388.61 ± 0.990.235
NLR, mean ± SEM8.2 ± 0.210.9 ± 2.10.099
Fibrinogen (mg/dL), mean ± SEM449.3 ± 12.1456.8 ± 30.30.986
D-dimer (ng/mL), mean ± SEM2005.6 ± 255.61903.3 ± 686.90.572
CFS Score, median (IQR)7 (4–8)7 (5–8)0.916
Table
Table 2. Frequency distribution of CMV positive patients in relation to in-hospital death after age-stratification.
Table 2. Frequency distribution of CMV positive patients in relation to in-hospital death after age-stratification.
CMV NegativeCMV Positive
Age ≤ 86Survivors, n (%)59 (86.8%)4 (50.0%)
Deceased, n (%)9 (13.2%)4 (50.0%) *
Age ≥ 87Survivors, n (%)38 (55.1%)6 (54.5%)
Deceased, n (%)31 (44.9%)5 (45.5%)
* Pearson’s χ2 = 6823, p = 0.009.
Table
Table 3. Multivariable cox regression analysis of associated factors with in-hospital mortality in COVID-19 patients stratified by age.
Table 3. Multivariable cox regression analysis of associated factors with in-hospital mortality in COVID-19 patients stratified by age.
HR95% CIp Value
≤86 age yrsage1.160.96–1.400.125
sex0.6260.14–2.780.538
disease count0.880.55–1.400.598
CRP1.171.05–1.300.005
CMV9.941.66–59.500.012
Neutrophil count1.201.01–1.420.038
CFS1.541.04–2.280.032
≥87 age yrsage1.151.01–1.310.031
sex1.670.69–4.020.254
disease count1.320.99–1.770.056
CRP1.0680.99–1.150.073
CMV0.3940.11–1.380.146
Neutrophil count1.131.05–1.210.001
CFS1.010.80–1.280.916
C-reactive protein (CRP); cytomegalovirus (CMV); and clinical frailty scale (CSF).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Giacconi, R.; Cardelli, M.; Piacenza, F.; Pierpaoli, E.; Farnocchia, E.; Di Rosa, M.; Bonfigli, A.R.; Casoli, T.; Marchegiani, F.; Marcheselli, F.; et al. Effect of Cytomegalovirus Reactivation on Inflammatory Status and Mortality of Older COVID-19 Patients. Int. J. Mol. Sci. 2023, 24, 6832. https://doi.org/10.3390/ijms24076832

AMA Style

Giacconi R, Cardelli M, Piacenza F, Pierpaoli E, Farnocchia E, Di Rosa M, Bonfigli AR, Casoli T, Marchegiani F, Marcheselli F, et al. Effect of Cytomegalovirus Reactivation on Inflammatory Status and Mortality of Older COVID-19 Patients. International Journal of Molecular Sciences. 2023; 24(7):6832. https://doi.org/10.3390/ijms24076832

Chicago/Turabian Style

Giacconi, Robertina, Maurizio Cardelli, Francesco Piacenza, Elisa Pierpaoli, Elisabetta Farnocchia, MirKo Di Rosa, Anna Rita Bonfigli, Tiziana Casoli, Francesca Marchegiani, Fiorella Marcheselli, and et al. 2023. "Effect of Cytomegalovirus Reactivation on Inflammatory Status and Mortality of Older COVID-19 Patients" International Journal of Molecular Sciences 24, no. 7: 6832. https://doi.org/10.3390/ijms24076832

APA Style

Giacconi, R., Cardelli, M., Piacenza, F., Pierpaoli, E., Farnocchia, E., Di Rosa, M., Bonfigli, A. R., Casoli, T., Marchegiani, F., Marcheselli, F., Recchioni, R., Stripoli, P., Galeazzi, R., Cherubini, A., Fedecostante, M., Sarzani, R., Di Pentima, C., Giordano, P., Antonicelli, R., ... Lattanzio, F. (2023). Effect of Cytomegalovirus Reactivation on Inflammatory Status and Mortality of Older COVID-19 Patients. International Journal of Molecular Sciences, 24(7), 6832. https://doi.org/10.3390/ijms24076832

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop